

Limosilactobacillus reuteri Protectis DSM 17938 versus placebo in children with acute gastroenteritis in a Pediatric Emergency Department

Iramain R, Jara A, Ortiz J, Cardozo L, Morinigo R. J Pediatr Gastroenterol Nutr. Published online 2025. doi:10.1002/jpn3.70026.


L. reuteri Protectis reduces diarrhea in children with AGE

Results

L. reuteri Protectis significantly reduced:

- Duration of diarrhea (2.77 ± 0.6 vs. 3.10 ± 1.1 days; $p = 0.036$)
- Number of watery stools on day 2, 3, 4 and 5 of treatment ($p < 0.001$)
- Percentage of patients with watery diarrhea on day 2 and 3 of treatment ($p < 0.01$)

Number of watery stools/day



L. reuteri Protectis significantly reduced the number of watery stools from day 2 and onwards ($p < 0.001$).

Conclusion

This study shows that *L. reuteri* Protectis is safe and efficient in reducing both frequency and consistency of stools in children with AGE.

Facts

- Study design: Randomized, double-blinded and placebo-controlled
- Subjects: 137 children aged 1 month to 5 years with AGE
- Dosage: 5 drops twice daily (2×10^8 CFU/day)
- Duration: 5 days
- Primary outcome: duration of diarrhea

Further reading

- Dinleyici EC, Group PS, Vandenplas Y. *Lactobacillus reuteri* DSM 17938 effectively reduces the duration of acute diarrhoea in hospitalised children. Acta Paediatr. 2014;103(7):e300-e305. doi:10.1111/apa.12617.
- Dinleyici EC, Dalgic N, Guven S, Metin O, Yasa O, Kurugol Z, et al. *Lactobacillus reuteri* DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting. J Pediatr. 2015;91(4):392-396. doi:10.1016/j.jpeds.2014.10.009.
- Francavilla R, Lionetti E, Castellaneta S, Ciruzzi F, Indrio F, Masciale A, et al. Randomised clinical trial: *Lactobacillus reuteri* DSM 17938 vs. placebo in children with acute diarrhoea - a double-blind study. Aliment Pharm Therap. 2012;36(4):363-369. doi:10.1111/j.1365-2036.2012.05180.x.